Erythropoiesis-Stimulating Agents in Oncology

Author： Glaspy John A.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.6, Iss.6, 2008-07, pp. : 565-575

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents

By Mei Sheng Duh  

PharmacoEconomics, Vol. 26, Iss. 2, 2008-01 ,pp. : 99-120

Adis International

Access to resources Recommend Favorite

Erythropoiesis-stimulating agents in patients with cancer: update on safety issues

By Pirker Robert  

Expert Opinion on Drug Safety, Vol. 8, Iss. 5, 2009-09 ,pp. : 515-522

Informa Healthcare

Access to resources Recommend Favorite

Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE): A Registry for Characterizing Anaemia Management and Outcomes in Oncology Patients

By Larholt Kay  

Clinical Drug Investigation, Vol. 28, Iss. 3, 2008-01 ,pp. : 159-167

Adis International

Access to resources Recommend Favorite

Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations

By Abraham Ivo   MacDonald Karen  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 885-887

Informa Healthcare

Access to resources Recommend Favorite

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

By Del Vecchio Lucia   Locatelli Francesco  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 923-931

Informa Healthcare

Access to resources Recommend Favorite